Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years

摘要: Abstract Background A 13-valent pneumococcal conjugate vaccine (PCV13) was recently developed for use in older adults, and may be effective not only against invasive disease (IPD) but also nonbacteremic pneumonia. The potential public health economic impact of PCV13 this population is unknown. Methods microsimulation model depicting risk costs IPD all-cause pneumonia (NBP) US adults aged ≥50 years ( n  = 96.1 million), as well expected vaccination, developed. Effectiveness PPSV23 based on published literature, NBP, zero; effectiveness PCV7 data children, varied across a reasonable range. Lifetime outcomes were projected assuming: (1) all subjects at entry, with without periodic revaccination; (2) per current ACIP recommendations. Results Use entry revaccination – lieu recommendations reduced cases by 15,000 (95% CI 9000–21,000); NBP 1.2 million (0.9–1.5); total healthcare $3.5 billion (1.9–5.2); societal $7.4 billion (5.3–9.8). every 5–10 years resulted fewest lowest costs. Findings largely unchanged sensitivity analyses. Conclusions Assuming that the comparable to observed children under assumptions regarding underlying risks projections suggest routine would result greater reduction overall burden adults.